Last reviewed · How we verify

NCT03871517

INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE

Completed Phase 4 Last updated 9 January 2023
What this trial tests

Phase 4 trial testing Indobufen in Ischemic Stroke in 5,438 participants. Completed in 1 December 2022.

Timeline
3 June 2019
Primary endpoint
1 March 2022
1 December 2022

Quick facts

Lead sponsorBeijing Tiantan Hospital
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment5,438
Start date3 June 2019
Primary completion1 March 2022
Estimated completion1 December 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 18 to 80, any sex, with Ischemic Stroke or Indobufen. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

China has the largest burden of cerebrovascular disease in the world. About 60% to 80% of which are ischemic stroke. In recent years, stroke has replaced heart disease and tumor diseases as the first cause of death and disability in adult population. The primary purpose of this study is to evaluate the efficacy of indobufen treatment in reducing the risk of a 3-month new stroke (any type of stroke, including ischemic stroke and hemorrhagic stroke) for patients with moderate/severe ischemic stroke is not inferior to aspirin therapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Systemic inflammation after stroke: implications for post-stroke comorbidities.
    Simats A, Liesz A. · · 2022 · cited 179× · PMID 35971650 · DOI 10.15252/emmm.202216269
  2. Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial.
    Pan Y, Meng X, Yuan B, Johnston SC, et al · · 2023 · cited 25× · PMID 37121237 · DOI 10.1016/s1474-4422(23)00113-8
  3. Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial.
    Pan Y, Meng X, Chen W, Jing J, et al · · 2022 · cited 7× · PMID 35393360 · DOI 10.1136/svn-2021-001480
  4. Effect of Stroke Severity on Efficacy and Safety of Indobufen versus Aspirin in Patients with Moderate to Severe Stroke: Results from the INSURE Randomized Clinical Trial.
    Wang M, Pu S, Jin A, Johnston SC, et al · · 2025 · PMID 40707193 · DOI 10.5551/jat.65723

Verify or expand the search:

Other trials of Indobufen

Trials testing the same drug.

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03871517.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing